benitec.com (BNTC) Company Cash Funds

benitec.com - graphic logo of issuer BNTC

Benitec Biopharma Inc. (BNTC) faces high binary risks due to its reliance on a single dysphagia treatment platform, a fact confirmed by the cash runway chart. The company leverages AI for therapy development and automates synthesis, while long-term patents for DNA drug delivery establish a foundation for future royalties. The current value of the metric is 0.18, demonstrating the asset's liquidity level.

Company Cash on Hand: Benitec Biopharma Inc (BNTC) for 07/04/2022 - 11/21/2026

Financial and market metric breakdowns for Benitec Biopharma (BNTC)

Basic company analysis:BNTC Benitec Biopharma
Product sample of benitec.com

The complex logistics of gene therapies and the maintenance of biomedical hubs require a constant influx of liquidity for Benitec Biopharma Inc. (BNTC). This indicator captures the daily cash balance, allowing for real-time tracking of the capital burn rate. It is critical for investors to distinguish between a strategic reserve and excessive asset freezing that reduces overall profitability. The price action of the cash balance clearly demonstrates the financial stability of current clinical projects.

Who Benitec Biopharma Inc. competes with

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|DSGN: Company Cash Volume|Company Cash and Cash Equivalents RCKT|Company Cash on Hand FDMT|Company Cash and Cash Equivalents LXEO (Lexeo Therapeutics)|Company Cash Volume KRRO|Editas Medicine, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume